Moderna’s covid vaccine shows 100% effectiveness in 12-18 year olds. And in this age group, “no significant safety issues” are encountered. This is what the US pharmaceutical company announces by communicating that the phase 2/3 TeenCOVE study on its vaccine (mRNA-1273) for adolescents reaches the primary endpoint of immunogenicity not lower than that of the adult comparison group of the phase study 3. High protection data are found already after the first shield injection, reports Moderna. Using the case definition of the Center for Disease Control and Prevention (Cdc), a vaccine efficacy of 93% was observed after the first dose. After the two doses, no cases of Covid-19 were observed, using the primary case definition. And this result is consistent with a vaccine efficacy of 100%. The TeenCOVE study enrolled more than 3,700 participants between the ages of 12 and 18 in the United States. Moderna will present “at the beginning of June” the results of the phase 2/3 study on its anti-Covid vaccine in adolescents aged 12 to 18 “to the US FDA and other regulatory bodies globally, asking for the authorization” of the product approved today for the population over 18. This was stated by Stéphane Bancel, CEO of the American pharmaceutical group. “We are encouraged by the fact that” the vaccine “mRna-1273 has been highly effective in preventing Covid-19 in adolescents – underlines the CEO – It is particularly exciting to see that the Moderna Covid-19 vaccine can prevent Sars-CoV-2 infection “, he adds, confirming the commitment” to do our part to help end the pandemic “.